Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Yet another combination to consider after CDK4/6i + ET in HR+ MBC!
Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study
Author(s): Tara Sanft, MD1,2; Maura Harrigan, RD, MS, CSO3; Courtney McGowan, RD, CSO3; Brenda Cartmel, PhD2,3; Michelle Zupa, BS3; Fang-Yong Li, MS3; Leah M. Ferrucci, PhD2,3; Leah Puklin, MPH3; Anlan Cao, BS3; Thai Hien Nguyen, MPH3; Marian L. Neuhouser, PhD4; Dawn L. Hershman, MD5; Karen Basen-Engquist, PhD6; Beth A. Jones, PhD2,3; Tish Knobf, PhD3,7; Anees B. Chagpar, MD, MPH1,2; Andrea Silber, MD1,2; Anna Tanasijevic, MPH8; Jennifer A. Ligibel, MD9; Melinda L. Irwin, PhD, MPH1,2
Source: https://doi.org/10.1200/JCO.23.00871
Dr. Maen Hussein's Thoughts
There have been studies showing decreased recurrence in women who underwent curative breast surgeries (walking and yoga). This study assesses if it will affect the intensity of chemotherapy delivered. Although it did not affect it, women who underwent the program had better pathologic complete response (pCR), we need more studies to assess role of nutrition and exercise in treating cancer as we develop a wholesome approach to treat our patients, something we may be able to do in our practice.
PURPOSE
Successful completion of chemotherapy is critical to improve breast cancer outcomes. Relative dose intensity (RDI), defined as the ratio of chemotherapy delivered to prescribed, is a measure of chemotherapy completion and is associated with cancer mortality. The effect of exercise and eating a healthy diet on RDI is unknown. We conducted a randomized trial of an exercise and nutrition intervention on RDI and pathologic complete response (pCR) in women diagnosed with breast cancer initiating chemotherapy.
METHODS
One hundred seventy-three women with stage I-III breast cancer were randomly assigned to usual care (UC; n = 86) or a home-based exercise and nutrition intervention with counseling sessions delivered by oncology-certified registered dietitians (n = 87). Chemotherapy dose adjustments and delays and pCR were abstracted from electronic medical records. T-tests and chi-square tests were used to examine the effect of the intervention versus UC on RDI and pCR.
RESULTS
Participants randomly assigned to intervention had greater improvements in exercise and diet quality compared with UC (P < .05). RDI was 92.9% ± 12.1% and 93.6% ± 11.1% for intervention and UC, respectively (P = .69); the proportion of patients in the intervention versus UC who achieved ≥85% RDI was 81% and 85%, respectively (P = .44). The proportion of patients who had at least one dose reduction and/or delay was 38% intervention and 36% UC (P = .80). Among 72 women who received neoadjuvant chemotherapy, women randomly assigned to intervention were more likely to have a pCR than those randomly assigned to UC (53% v 28%; P = .037).
CONCLUSION
Although a diet and exercise intervention did not affect RDI, the intervention was associated with a higher pCR in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative and triple-negative breast cancer undergoing neoadjuvant chemotherapy.
Author Affiliations
1Yale University School of Medicine, New Haven, CT; 2Yale Cancer Center, New Haven, CT; 3Yale School of Public Health, New Haven, CT; 4Fred Hutchinson Cancer Research Center, Seattle, WA; 5Columbia University Medical Center, New York, NY; 6The University of Texas MD Anderson Cancer Center, Houston, TX; 7Yale School of Nursing, New Haven, CT; 8Dana-Farber Cancer Institute, Boston, MA; 9Dana-Farber Cancer Institute, Boston, MARelated Articles
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
The INSEMA trial showed that for early stage, T1-T2 clinically node negative breast cancer, sentinel lymph node biopsies should not be mandatory, and best clinical judgement can be used.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant (novel oral SERD) was active in patients with an ESR1 mutations, but otherwise did not offer a benefit in this population of women with ER+ HER2-neg MBC. Overall survival (OS) data is pending with further follow up.
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
Another trial with neoadjuvant immunotherapy showing improved results over chemotherapy alone. (12% higher PCR 48% vs 36%).
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Dato-DXd is now approved in HR+, HER2-neg, metastatic breast cancer after prior therapy with endocrine-based therapy and chemotherapy. There was an impressive reduction in the risk of death or progression with an HR of 0.63. Watch out for ocular and pulmonary toxicity. HER2-ultra low testing will be burdensome but must be done for drug approval.
